Please login to the form below

AZD3293

This page shows the latest AZD3293 news and features for those working in and with pharma, biotech and healthcare.

Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat

The demise of the BACE1 inhibitor – also known as AZD3293/LY3314814 – adds to the litany of failures among drugs intended to treat Alzheimer’s, and specifically those trying to slow down

Latest news

Biogen rises on more positive data for Alzheimer's candidate

compounds. . Last week, it partnered with AstraZeneca (AZ) on MEDI1814, an antibody against amyloid-beta 42 (Aβ42) in phase I trials, and is also working with AZ on BACE inhibitor AZD3293,
Lilly taps AstraZeneca for another anti-amyloid drug

The two companies are already working together on AZD3293, a BACE inhibitor which is designed to interrupt the formation of Aβ at an early stage in the process, and are running
Lilly sinks as solanezumab fails again in Alzheimer's

AZD3293. Ricks has previously suggested that if EXPEDITION3 was a bust then the expensive, 2, 500-patient prodromal trial will probably be abandoned.
AZ-Lilly start second pivotal trial of fast-tracked Alzheimer's drug

AMARANTH could be first treatment to target underlying mechanism. . AstraZeneca and Eli Lilly's collaboration in Alzheimer's disease continues to make progress, as their AZD3293 drug is granted a ... AZ and Lilly are already carrying out one phase
Eisai and Biogen plan phase III trials for Alzheimer's drug

others. Merck has already started phase III trials of its MK-8931 candidate, while Lilly and AZ recently did likewise with AZD3293.

More from news
Approximately 1 fully matching, plus 12 partially matching documents found.

Latest Intelligence

Deal Watch October 2016

Lilly. AZD3293. $500 profit share. Neurology 2012. Impax US. Zomig US.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Account Director, Medical Education: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Editor – Medical Education Agency – Bucks: Salary TBC

Senior Medical Writer: Salary TBC

Director – Healthcare PR: Salary TBC

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Senior Medical Writer: Competitive salary and benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

NEW FREELANCE OPPORTUNITIES!!! LONDON and HOME WORKING!: EXCELLENT DAY RATES AVAILABLE

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Subscribe to our email news alerts

PMHub

Add my company

Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...